The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.
Nature. 2012 Jun 20;486(7403):405-9. doi: 10.1038/nature11154.
Breast carcinoma is the leading cause of cancer-related mortality in women worldwide, with an estimated 1.38 million new cases and 458,000 deaths in 2008 alone. This malignancy represents a heterogeneous group of tumours with characteristic molecular features, prognosis and responses to available therapy. Recurrent somatic alterations in breast cancer have been described, including mutations and copy number alterations, notably ERBB2 amplifications, the first successful therapy target defined by a genomic aberration. Previous DNA sequencing studies of breast cancer genomes have revealed additional candidate mutations and gene rearrangements. Here we report the whole-exome sequences of DNA from 103 human breast cancers of diverse subtypes from patients in Mexico and Vietnam compared to matched-normal DNA, together with whole-genome sequences of 22 breast cancer/normal pairs. Beyond confirming recurrent somatic mutations in PIK3CA, TP53, AKT1, GATA3 and MAP3K1, we discovered recurrent mutations in the CBFB transcription factor gene and deletions of its partner RUNX1. Furthermore, we have identified a recurrent MAGI3-AKT3 fusion enriched in triple-negative breast cancer lacking oestrogen and progesterone receptors and ERBB2 expression. The MAGI3-AKT3 fusion leads to constitutive activation of AKT kinase, which is abolished by treatment with an ATP-competitive AKT small-molecule inhibitor.
乳腺癌是全世界女性癌症相关死亡的主要原因,仅在 2008 年就估计有 138 万新发病例和 45.8 万死亡病例。这种恶性肿瘤代表了一组具有特征性分子特征、预后和对现有治疗反应的异质性肿瘤。乳腺癌中已经描述了复发性体细胞改变,包括突变和拷贝数改变,特别是 ERBB2 扩增,这是第一个由基因组异常定义的成功治疗靶点。以前对乳腺癌基因组的 DNA 测序研究揭示了其他候选突变和基因重排。在这里,我们报告了来自墨西哥和越南的 103 例不同亚型的人类乳腺癌的全外显子组 DNA 序列,与匹配的正常 DNA 进行了比较,同时还报告了 22 对乳腺癌/正常对的全基因组序列。除了证实 PIK3CA、TP53、AKT1、GATA3 和 MAP3K1 中的复发性体细胞突变外,我们还发现了 CBFB 转录因子基因中的复发性突变和其伴侣 RUNX1 的缺失。此外,我们还鉴定了一种在缺乏雌激素和孕激素受体和 ERBB2 表达的三阴性乳腺癌中富集的 MAGI3-AKT3 融合。MAGI3-AKT3 融合导致 AKT 激酶的组成性激活,用 ATP 竞争性 AKT 小分子抑制剂处理可消除 AKT 激酶的激活。